Flexion Therapeutics Company Profile (NASDAQ:FLXN)

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Flexion Therapeutics, Inc. (NASDAQ:FLXN) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.02. View Flexion Therapeutics' Earnings History.

8 brokers have issued twelve-month target prices for Flexion Therapeutics' shares. Their forecasts range from $0.02 to $44.00. On average, they anticipate Flexion Therapeutics' share price to reach $31.56 in the next year. View Analyst Ratings for Flexion Therapeutics.

Here are some recent quotes from research analysts about Flexion Therapeutics stock:

• 1. According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (5/9/2017)
• 2. Cantor Fitzgerald analysts commented, "OpEx Increases in 2017: FLXN reported 4Q16 and YE results of ($0.79) and ($2.84), below our estimates due to higher R&D and SG&A expense. Management noted on the call that R&D expense should increase given the on going repeat-dose study and manufacturing ramp with SG&A ramping through the 2H17 as launch preparation get fully underway. FLXN finished the quarter with $210M in cash which we estimate gives them funding through mid-2018. We have adjusted our estimates to reflect quarter results. PDUFA and Beyond: We view the acceptance of the NDA without the need to provide additional data as an incremental positive, removing an overhang in the minds of some investors. We see investors now turning to the prospective label with the potential for differentiation in the diabetic sub-population and a repeat- dose sNDA filing which could be on label by 2019. Additional label expansion into other joints including shoulder and hip are also possibilities though not near term." (3/14/2017)
• 3. BMO Capital Markets analysts commented, "While the company did not receive a priority review, we had not been expecting that, and had always assumed a standard 10-month review. It was good to see the FDA accept the NDA with no major issues, and we remain confident in the approval of Zilretta at the PDUFA. Reiterate our Outperform; FLXN remains a top pick." (2/7/2017)

Some companies that are related to Flexion Therapeutics include Dermira (DERM), Acceleron Pharma (XLRN), Insmed (INSM), Synergy Pharmaceuticals (SGYP), Omeros Corporation (OMER), Forward Pharma A/S (FWP), Clinigen Group PLC (CLIN), Amarin Corporation PLC (AMRN), Xencor (XNCR), Insys Therapeutics (INSY), Acorda Therapeutics (ACOR), Five Prime Therapeutics (FPRX), Achaogen (AKAO), ZIOPHARM Oncology (ZIOP), Epizyme (EPZM), Ascendis Pharma A/S (ASND), Coherus BioSciences (CHRS) and Revance Therapeutics (RVNC).

Flexion Therapeutics' management team includes the folowing people:

• Patrick J. Mahaffy, Chairman of the Board
• Michael D. Clayman M.D., President, Chief Executive Officer, Co-Founder, Director
• Neil Bodick M.D., Ph.D., Chief Scientific Officer
• John Magee, Vice President - Sales
• Mark Fraga, Vice President - Marketing
• Scott Kelley M.D., Vice President - Medical Affairs
• Dan Thornton, Vice President - Market Access
• Yamo Deniz M.D., Chief Medical Officer
• Mark P. Stejbach, Director
• Scott A. Canute, Independent Director

Flexion Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (13.50%), Bank of New York Mellon Corp (6.69%), Vanguard Group Inc. (3.14%), TPG Group Holdings SBS Advisors Inc. (2.95%), State Street Corp (2.61%) and Peregrine Capital Management LLC (2.25%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick and Samuel D Colella. View Institutional Ownership Trends for Flexion Therapeutics.

Flexion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Gilder Gagnon Howe & Co. LLC, Morgan Stanley, Peregrine Capital Management LLC, JPMorgan Chase & Co., Highbridge Capital Management LLC, Public Employees Retirement System of Ohio and Russell Investments Group Ltd.. Company insiders that have sold Flexion Therapeutics stock in the last year include Frederick W Driscoll and Neil Bodick. View Insider Buying and Selling for Flexion Therapeutics.

Flexion Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Pictet Asset Management Ltd., Bank of New York Mellon Corp, Ionic Capital Management LLC, EAM Investors LLC, Canada Pension Plan Investment Board, Driehaus Capital Management LLC and Mirae Asset Global Investments Co. Ltd.. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick and Samuel D Colella. View Insider Buying and Selling for Flexion Therapeutics.

Shares of Flexion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Flexion Therapeutics stock can currently be purchased for approximately $21.56.